political and professional reasons. 1 Active involvement in government-driven quality improvement initiatives may therefore be resisted because that appears to be tantamount to endorsing a particular programme of reform or because it is feared that involvement may be seen as consent to further change.
At a local level, involvement in quality improvement initiatives is likely to require working collaboratively with managers, with whom the medical profession has historically been at odds. 11 At the inter-professional level, many quality improvement initiatives require changes in the traditional division of labour between health professionals 5 and may require some health professionals to give up aspects of their autonomy, leadership or status. In summary, active engagement in quality improvement is likely to entail profound and disconcerting changes, greater uncertainty, and some potential loss of face for individuals and professions in acknowledging other parties, giving up cherished turf and altering everyday routines and established ceremonies.
Engaging clinicians in quality improvement will therefore require addressing these underlying issues and finding creative ways to mobilise health professionals' knowledge and experience to change services. Arguably, it will also require policy-makers, managers and health professionals to acknowledge and leave behind the mistakes of the past: 9 the failure to allocate time and resources to quality improvement activities; the over-enthusiastic adoption and misapplication of elements of commercial quality programmes; the turbulence created by multiple conflicting change initiatives; the reliance on poor quality data; and any easy retreat behind the rhetoric of professionalism or clinical autonomy.
Of course, not all clinicians are resistant to engagement. Many can and do get involved, sometimes passionately and for sustained periods. Nevertheless, there is widespread disengagement and multiple reasons for it. Understanding this complex and subtle dynamic is a vital first step to the development of more varied, honed and effective strategies of clinician engagement. Without such engagement, health services will not be able to secure high quality care for all patients.
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Health technology guidance, particularly with respect to the adoption of new health technologies, is becoming increasingly prominent in many countries. While the greatest interest to date has been shown in pharmaceuticals, Virginia Warren in this issue turns attention to their poor cousin -interventional procedures. 1 Although the data presented for England comes from a period in which the National Institute for Health and Clinical Excellence (NICE) may have been on a learning curve and facing a backlog, readers cannot fail to be struck by the marked differences in timingassessments taking over a year for NICE and within 48 hours for a private health insurance company (BUPA), with the latter's decisions appearing two years ahead of those of NICE. A natural question to ask is whether differences in timing lead to different decisions. It is clear that the conclusions reached have been similar. political and professional reasons. 1 Active involvement in government-driven quality improvement initiatives may therefore be resisted because that appears to be tantamount to endorsing a particular programme of reform or because it is feared that involvement may be seen as consent to further change.
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Editorials
Slow slow, quick quick slow: the health technology guidance tango
This echoes observations which have been made comparing the decisions made by the Scottish Medicines Consortium (SMC) and NICE with respect to new pharmaceuticals. Crudely, SMC decisions have been quick and those of NICE have, by comparison, been slow but the decisions have been similar. 2 Given the higher public and political profile of new medicines this has led to NICE introducing their own rapid (or semifast) Single Technology Appraisal stream while retaining their slower traditional approach (now termed Multiple Technology Appraisal).
Is NICE guidance with respect to interventional procedures also a candidate for reform? Certainly the dramatic comparison presented by Warren suggests a prima facie case. However, the optimal timing of guidance on interventional procedures is a complex issue. At least two questions with respect to timing should be distinguished: at what stage in the development of an interventional procedure should guidance be produced and how rapidly should a decision be reached. NICE and BUPA have different remits and they are accountable to different parties. The costs and benefits to an agency with national responsibilities as opposed to a private company are likely to differ. As a result they can be expected to reach different conclusions regarding not only when to make a decision but also how rapidly it is feasible and necessary to complete the process.
If, as a matter of principle, processes are consultative and provide opportunities for decisions to be subject to appeal, there are limits to how rapidly guidance can be issued. However, it seems likely that there is scope to speed up the current processes used by NICE. In determining whether or not NICE should change their approach to assessing new interventional procedures it is important to identify what are the costs and benefits of more rapid decision making for such agencies. Are decisions taking so long that health care providers are disadvantaged by having to invest time and energy in making interim assessments? To what extent does the absence or presence of NICE guidance influence the extent and speed of adoption of different procedures? On balance, are patients being disadvantaged by the later adoption of interventional procedures or protected by the current approach. Could the additional resources it might take to provide more rapid appraisal of interventional procedures be better spent on some of NICE's other activities? Neither NICE nor BUPA consider cost-effectiveness as a criterion in the case of interventional procedures. Given that NICE places considerable emphasis on cost-effectiveness when appraising health technologies, and also increasingly when developing clinical guidelines, insights into the likely cost-effectiveness of new interventional procedures may be of greater value than simply providing pronouncements on safety and efficacy more rapidly.
